Steris (STE)
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$224.59-0.99%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · STE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 4.4% |
| Our one-year growth estimate | diamond | 7.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
STE — strategy / product update — Costs Associated with Exit or Disposal Activities
Dated 2026-08-05
Costs Associated with Exit or Disposal Activities. On August 5, 2026, the Company announced a targeted consolidation plan (the “Consolidation Plan”) to consolidate existing manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina. The investment is expected to accelerate innovation, expand capacity and optimize our U.S. chemistries manufacturing and distribution network. The Consolidation Plan includes the anticipated closure of chemistry manuf…
Why it matters: Free cash flow is crucial for STERIS's financial health. A drop may limit growth.
Worry ifFree cash flow reported below $850 million for fiscal 2027.
Less concerning ifFree cash flow reported at $850 million or higher for fiscal 2027.
Why it matters: Spending more than this amount may show financial problems or poor resource use.
Worry ifCapital spending is over $375M.
Less concerning ifCapital spending is at or below $375M.
Why it matters: Changes in leadership can change company plans and affect investor trust. It is important to watch this.
Watch forNew leaders say positive things about future plans and growth.
Also watch forStakeholders have negative views or doubts about the leadership change.
Why it matters: A successful sale will help STERIS focus on main markets and lower debt.
Supportive ifThe divestiture of the Dental segment closes as planned in fiscal 2025.
Worry ifDelays or regulatory problems may stop the sale from closing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$115 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $262 loss on $10,000 · 2.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,559 loss on $10,000 · 25.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing the restructuring plan on time shows strong management skills.
Supportive ifThe restructuring plan is done on time by fiscal 2030.
Worry ifThe restructuring plan is delayed past fiscal 2030.
Why it matters: The outlook will reflect the impact of the Dental segment divestiture on future growth.
Watch forManagement thinks they will do well in fiscal 2025. This is after selling part of the business.
Also watch forManagement is careful about fiscal 2025. They see some challenges ahead.
Why it matters: The restructuring plan aims to improve operations. Finishing it shows good management and cost control.
Watch forCompletion of the restructuring plan with costs within the $55M to $70M range.
Also watch forDelays or cost overruns beyond the $70M threshold.
Why it matters: This could indicate a broader slowdown in the healthcare sector affecting STERIS.
Worry ifHealthcare sector revenue growth reported below its median.
Less concerning ifHealthcare sector revenue growth remains at or above its median.
Why it matters: Leadership changes can impact strategy and performance. Clarity on the new CEO's vision is crucial.
Watch forThe new CEO outlines a clear strategy and goals within the next quarter.
Also watch forThere is still uncertainty about the new CEO's plans.
Why it matters: Maintaining this growth range is key for STERIS's performance and investor confidence.
Supportive ifIn fiscal 2027, revenue growth is expected to be between 7-8% as management said.
Worry ifRevenue growth falls below 7% for the fiscal year.
Why it matters: This would indicate STERIS is not on track to meet its growth target for fiscal 2026.
Worry ifQ2 revenue growth reported below 8% year over year.
Less concerning ifQ2 revenue growth stays at or above 8% year over year.
Why it matters: Meeting this goal is important for future growth and operations.
Supportive ifFree cash flow for fiscal 2027 meets or exceeds $800 million.
Worry ifFree cash flow falls below $750 million.
Why it matters: Higher costs may show problems in operations. This can hurt profits.
Worry ifTotal pre-tax restructuring charges are more than $70 million.
Less concerning ifRestructuring costs are under $55 million.
Why it matters: The sale allows STERIS to focus on core markets. Success in this shift could enhance overall performance.
Watch forThe divestiture is complete. The money will be used to pay down debt.
Also watch forDelays in closing the transaction or failure to use proceeds for debt repayment.
Why it matters: The outlook will reflect the impact of the Dental segment sale on future revenue growth.
Watch forManagement expects revenue growth above 7% for fiscal 2025. This shows strong growth potential.
Also watch forManagement expects revenue growth below 7% for fiscal 2025. This is a lower outlook.
Why it matters: New guidance will show how the divestiture impacts STERIS's growth outlook. It will clarify future revenue expectations.
Watch forManagement gives revenue guidance for fiscal 2025. This shows a positive outlook.
Also watch forManagement gives guidance that shows a drop or no change in revenue expectations.
Why it matters: Hitting this target shows strong demand. It helps management's growth plan for fiscal 2027.
Supportive ifQ2 revenue growth of 7% or more compared to the same quarter last year.
Worry ifQ2 revenue growth falls below 6%, indicating weaker demand.